Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

Taha Koray Sahin, Fatih Kemik, Harun Muglu, Bedriye Acikgöz Yildiz, Sedat Biter, Salih Tunbekici, Ahmet Oruc, Ali Kaan Guren, Kerim Kaban, Halil Goksel Guzel, Cihan Erol, Musa Baris Aykan, Bahadir Koylu, Omer Burak Ekinci, Ilknur Deliktas Onur, Ali Kalem, Oguz Altunok, Mustafa Seyyar, Bunyamin Guney, Orhun Akdogan, Rashad Ismayilov, Fadime Sinem Ardic, Melike Yazici, Nargiz Majidova, Sema Turker, Ece Esin, Devrim Cabuk, Hatime Arzu Yasar, Arzu Oguz, Ozan Yazici, Riza Umar Gursu, Mesut Yılmaz, Havva Yesil Cinkir, Ozturk Ates, Emir Celik, Nuri Karadurmus, Umut Demirci, Banu Ozturk, Nil Molinas Mandel, Ibrahim Vedat Bayoglu, Murat Araz, Erdem Goker, Ertugrul Bayram, Dilek Erdem, Fatih Selcukbiricik, Gul Basaran, Ahmet Sezer, Gamze Gokoz Dogu, Yasemin Kemal, Ahmet Bilici, Seyda Gunduz, Deniz Can Guven, Sercan Aksoy

Therapeutic Advances in Medical Oncology

Published online on March 14, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Trastuzumab deruxtecan (T-DXd) has transformed the treatment landscape of human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC), with significant improvements in survival reported in clinical trials. However, ...